ClinicalTrialsFinder

HR+/HER2-negative Breast Cancer Clinical Trials in Cleveland, Ohio

1 recruitingCleveland, Ohio

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Metastatic Breast CancerHR+/HER2-negative Breast Cancer
SynDevRx, Inc.52 enrolled10 locationsNCT05455619